China Diabetes Cardiovascular Initiative

Registration

Registration

NCT05037058

Acronym

CDCV

Study type

OBSERVATIONAL

Status

UNKNOWN

Enrollment

9600

Start

2021-09-01

Primary completion

2023-12-31

Lead sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Conditions

Acute Coronary Syndrome; Diabetes Mellitus

Interventions

OTHER:Quality improvement activities

Results posted

FALSE

Registered primary outcomes

• Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours) [Duration of hospital stay, an expected average of 1 week]
• Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment [Duration of hospital stay, an expected average of 1 week]
• Proportion of STEMI patients receiving reperfusion therapy by PCI [Duration of hospital stay, an expected average of 1 week]
• Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment [Duration of hospital stay, an expected average of 1 week]
• Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival) [Duration of hospital stay, an expected average of 1 week]
• Proportion of NSTE-ACS patients receiving risk stratification at admission [Duration of hospital stay, an expected average of 1 week]
• Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients prescribed dual antiplatelet medications at discharge [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients with indications prescribed a beta-blocker at discharge [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients prescribed a statin at discharge [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients with indications prescribed an ACE-I or ARB at discharge [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients that receiving an LDL-C assessment [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients with evaluation for LV systolic function by echocardiography [Duration of hospital stay, an expected average of 1 week]
• Proportion of smoking patients that receiving smoking cessation advice/counseling [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients receiving fasting glucose test at least twice [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients receiving HbA1C test [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients with body height and weight measured and documented [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients receiving guidance on individualized dietary [Duration of hospital stay, an expected average of 1 week]
• Proportion of patients receiving guidance on individualized physical activity [Duration of hospital stay, an expected average of 1 week]